The effect of burosumab on intact and C-terminal FGF23 measurements.

Susan Louise Ashrafzadeh-KianNobuaki ItoTarak SrivastavaUttam GargHajime KatoAlicia Algeciras-SchimnichJoshua A Bornhorst

Published in: Clinical endocrinology (2022)

This article describes a negative analytical interference by burosumab in an intact FGF23 immunoassay. The recovery of C-terminal FGF23 is not significantly affected by the presence of burosumab. In vivo, both assays demonstrate extreme FGF23 elevations in the presence of the drug. Furthermore, the measurement of FGF23 blocked by burosumab is not clinically useful regarding hypophosphataemia.

Keyphrases

climate change
emergency department
high throughput